AKBA insider transaction filings
Akebia Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-10. Screen AKBA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 56,019 shares, $62,181 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 56,019 shares @ $1.11 ($62,181) by Ostrowski Erik, filed 2026-07-01.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Ostrowski Erik — SVP, CFO, CBO & Treasurer | 1 | — | 1 leg · 56,019 sh · $62,181 | — |
| Butler John P. — CEO and President, Director | 1 | — | — | 2 |
Recent Form 4 filings — Akebia Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-10 | 4 | Butler John P. — CEO and President, Director | Option exercise (M): 350,000 @ $0.63 · Option exercise (M): 350,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Ostrowski Erik — SVP, CFO, CBO & Treasurer | Sale (S): 56,019 @ $1.11 | EDGAR |
| 2026-06-22 | 4 | FRIESON RON — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Wolf Myles — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Smith Cynthia — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | ADAMS ADRIAN — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | ROGERS MICHAEL W — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | ZUMWALT LEANNE M — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Vickers Philip J. — Director | Grant/award (A): 214,400 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Butler John P. — CEO and President, Director | Purchase (P): 69,270 @ $1.25 | EDGAR |
| 2026-02-04 | 4 | Rucci Carolyn M. — SVP, Chief Legal Officer | Sale (S): 16,846 @ $1.39 · Sale (S): 25,382 @ $1.39 · Sale (S): 27,544 @ $1.39 | EDGAR |
| 2026-02-04 | 4 | Malabre Richard C — SVP, Chief Accounting Officer | Sale (S): 36,142 @ $1.39 · Sale (S): 13,382 @ $1.39 | EDGAR |
| 2026-02-04 | 4 | Ostrowski Erik — SVP, CFO, CBO & Treasurer | Sale (S): 34,951 @ $1.39 | EDGAR |
| 2026-02-04 | 4 | Grund Nicholas — Chief Commercial Officer | Sale (S): 53,585 @ $1.39 · Sale (S): 31,244 @ $1.39 | EDGAR |
| 2026-02-04 | 4 | Burke Steven Keith — SVP, Chief Medical Officer | Sale (S): 21,582 @ $1.39 · Sale (S): 25,375 @ $1.39 · Sale (S): 20,701 @ $1.39 | EDGAR |
| 2026-02-04 | 4 | Butler John P. — CEO and President, Director | Sale (S): 46,660 @ $1.39 · Sale (S): 96,065 @ $1.39 · Sale (S): 114,891 @ $1.39 · Grant/award (A): 175,250 @ $1.41 · Sale (S): 83,689 @ $1.39 | EDGAR |
| 2026-02-03 | 4 | Rucci Carolyn M. — SVP, Chief Legal Officer | Grant/award (A): 190,000 @ $0 · Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Malabre Richard C — SVP, Chief Accounting Officer | Grant/award (A): 79,000 @ $0 · Grant/award (A): 119,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Ostrowski Erik — SVP, CFO, CBO & Treasurer | Grant/award (A): 204,000 @ $0 · Grant/award (A): 320,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Grund Nicholas — Chief Commercial Officer | Grant/award (A): 204,000 @ $0 · Grant/award (A): 320,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Burke Steven Keith — SVP, Chief Medical Officer | Grant/award (A): 204,000 @ $0 · Grant/award (A): 320,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Butler John P. — CEO and President, Director | Grant/award (A): 743,000 @ $0 · Grant/award (A): 1,115,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Ostrowski Erik — SVP, CFO, CBO & Treasurer | Sale (S): 41,314 @ $3.67 | EDGAR |
| 2025-06-11 | 4 | Wolf Myles — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Smith Cynthia — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | FRIESON RON — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Malabre Richard C — SVP, Chief Accounting Officer | Option exercise (M): 15,000 @ $1.68 · Sale (S): 15,000 @ $4.01 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | GILMAN STEVEN C — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | ADAMS ADRIAN — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | ROGERS MICHAEL W — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | ZUMWALT LEANNE M — Director | Grant/award (A): 35,700 @ $0 · Grant/award (A): 53,600 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Malabre Richard C — SVP, Chief Accounting Officer | Sale (S): 13,334 @ $3.53 | EDGAR |
| 2025-03-04 | 4 | Butler John P. — CEO and President, Director | Sale (S): 46,409 @ $1.83 | EDGAR |
| 2025-03-04 | 4 | Burke Steven Keith — SVP, Chief Medical Officer | Sale (S): 7,144 @ $1.83 | EDGAR |
| 2025-02-04 | 4 | Butler John P. — CEO and President, Director | Grant/award (A): 701,000 @ $0 · Sale (S): 46,268 @ $2.10 · Sale (S): 97,982 @ $2.10 · Grant/award (A): 350,500 (derivative) @ $0 · Grant/award (A): 1,051,400 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Burke Steven Keith — SVP, Chief Medical Officer | Grant/award (A): 194,900 @ $0 · Sale (S): 23,270 @ $2.10 · Sale (S): 27,236 @ $2.10 · Grant/award (A): 292,300 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Malabre Richard C — SVP, Chief Accounting Officer | Grant/award (A): 85,000 @ $0 · Sale (S): 30,202 @ $2.10 · Grant/award (A): 128,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Grund Nicholas — Chief Commercial Officer | Grant/award (A): 194,900 @ $0 · Sale (S): 55,621 @ $2.10 · Grant/award (A): 292,300 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Ostrowski Erik — SVP, CFO, CBO & Treasurer | Grant/award (A): 194,900 @ $0 · Grant/award (A): 292,300 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | FRIESON RON — Director | Option exercise (M): 20,100 @ $0.45 · Option exercise (M): 20,100 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Ostrowski Erik — SVP, CFO, CBO & Treasurer | Grant/award (A): 350,000 @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Wolf Myles — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Smith Cynthia — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | FRIESON RON — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | GILMAN STEVEN C — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | ADAMS ADRIAN — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | ROGERS MICHAEL W — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | ZUMWALT LEANNE M — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Hadas Nicole R. — SVP, Chief Legal Officer | Sale (S): 12,016 @ $1.26 | EDGAR |
| 2024-05-14 | 4 | Dahan Michel — SVP, Chief Operating Officer | Sale (S): 34,840 @ $1.26 | EDGAR |
Recent 8-K events — Akebia Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AKBA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →